HTB

World AIDS 24 Montreal 2022

Metabolic complications of newer HIV drugs in older people

24th International AIDS Conference (AIDS 2022): further reports

AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3

AIDS 2022: Gender-affirming hormones, weight gain and ART

24th International AIDS Conference (AIDS 2022)

Dolutegravir no longer linked to higher risk of neural tube defects: latest update from the Tsepamo study

Weight gain with dolutegravir and TAF in ADVANCE study continues out to week 192

VRC01 added to early ART in infants did not reduce viral reservoir

Using PrEP during pregnancy is safe for children

Long-acting CAB/RPV injections have a similar weight and lipid profile to dolutegravir-based oral ART

Montreal’s response to monkeypox: rapid vaccine rollout, 39 breakthrough infections

Summary of 620 cases of monkeypox seen at three London clinics

Advances in HIV cure-related research: IAS workshop now online

24th International AIDS Conference (AIDS 2022): first reports

Dolutegravir-based ART in children and adolescents: effective in six African countries

Early data on injecting CAB/RPV-LA into thigh muscle

Doxycycline PEP significantly reduces STIs in people at high risk of infections

Another possible HIV cure case after stem cell transplantation for cancer; example of extended post-treatment control in Spain

Other cure-related sessions at AIDS 2022

Selected reports launched at AIDS 2022